BRM421 not checked
BRIM Biotechnology Inc. · BRM424
FollowEvery change as it happens, and a Monday email
Trials
1 active
5 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Dry Eye Disease (DED), Keratoconjunctivitis Sicca
- Main trialPhase 2
- “To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to artificial tear for treatment of the signs and symptoms of dry eye disease (DED)”In the company’s words, NCT07078955 on ClinicalTrials.gov
- Other names
- BRM424
Other drugs for Dry Eye Disease (DED)
- LicaminlimabOculis · Phase 2/3
- NipocalimabJohnson & Johnson (Janssen) · Phase 3
- VVN001VivaVision Biotech, Inc · Phase 3
- CAM-101Cambium Bio Limited · Phase 3
- TelitaciceptVor Biopharma · Phase 3
- OT202Ocumension Therapeutics (Shanghai) Co., Ltd · Phase 3
Coming up1
- NovPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Nov 2026 | A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease | |
| Phase 3Completed | 30 Dec 2023 | Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects. | |
| Phase 2/3Completed | 23 Jun 2020 | Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment | |
| Phase 2Completed | 20 May 2017 | Safety and Efficacy of BRM421 for Dry Eye Syndrome | |
| Phase 2Unknown | 30 Aug 2025 | Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026